Pediatric Inflammatory Bowel Disease Clinical Innovations Meeting of the Crohn’s & Colitis Foundation: Charting the Future of Pediatric IBD

Author:

Picoraro Joseph A1,Lee Dale2,Heller Caren A3,Weaver Alandra3,Hyams Jeffrey S4,Conklin Laurie S56,Otley Anthony7,Ziring David8,Kugathasan Subra9,Rosh Joel R10,Mulberg Andrew11,Denson Lee A12,Kappelman Michael D13,Grossman Andrew B14,Bousvaros Athos15,Park K T16

Affiliation:

1. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Medical Center, New York, New York

2. Division of Pediatric Gastroenterology and Hepatology, Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, Washington

3. Crohn’s & Colitis Foundation, New York, New York

4. Division of Gastroenterology, Hepatology, and Nutrition, Connecticut Children’s Medical Center, Hartford, Connecticut

5. Division of Gastroenterology, Hepatology, and Nutrition, Children’s National Medical Center, Washington, DC

6. ReveraGen Biopharma, LLC, Rockville, Maryland

7. Division of Gastroenterology and Nutrition, IWK Health Centre, Halifax, Nova Scotia, Canada

8. Pediatric Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California

9. Division of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, Georgia

10. Pediatric Gastroenterology, Clinical Development and Research Affairs, Goryeb Children’s Hospital/Atlantic Health, Morristown, New Jersey

11. Amicus Therapeutics, Cranbury, New Jersey

12. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio

13. Division of Pediatric Gastroenterology, University of North Carolina Chapel Hill, Chapel Hill, North Carolina

14. Division of Gastroenterology, Hepatology and Nutrition, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

15. Division of Gastroenterology, Hepatology and Nutrition, Boston Children’s Hospital, Boston, Massachusetts

16. Division of Gastroenterology, Hepatology and Nutrition, Stanford University School of Medicine, Palo Alto, California

Abstract

Abstract The Crohn’s & Colitis Foundation has facilitated transformational research in pediatric inflammatory bowel disease (IBD), through the RISK and PROTECT studies, that has laid the groundwork for a comprehensive understanding of molecular mechanisms of disease and predictors of therapeutic response in children. Despite these advances, children have lacked timely and informed access to the latest therapeutic advancements in IBD. The Crohn's & Colitis Foundation convened a Pediatric Resource Organization for Kids with Inflammatory Intestinal Diseases (PRO-KIIDS) Clinical Innovations Meeting at the inaugural Crohn's and Colitis Congress in January 2018 to devise how to advance the care of children with IBD. The working group selected 2 priorities: (1) accelerating therapies to children with IBD and (2) stimulating investigator-initiated research while fostering sustainable collaboration; and proposed 2 actions: (a) the convening of a task force to specifically address how to accelerate pharmacotherapies to children with IBD and (b) the funding of a multicenter clinical and translational research study that incorporates the building of critical research infrastructure. 10.1093/ibd/izy205_video1 izy205.video1 5799266615001

Funder

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases

Crohn‘s & Colitis Foundation

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3